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Summary
Epigenetic regulation of gene expression significantly influences cell growth and differentiation. Here we show that epige-
netic silencing of Fas determines tumor growth in vivo and apoptotic sensitivity in vitro. In established tumors with
epigenetically repressed Fas, restoration of Fas activity either by transfection of fas or treatment with Trichostatin A
(TSA), an inhibitor of histone deacetylase, suppresses tumor growth and restores chemosensitivity. The TSA-dependent
chemosensitivity and tumor growth control require both tumor Fas and the host NK (natural killer) cell functions. This work
demonstrates the importance of epigenetic modification of Fas in tumor progression and immune evasion, and emphasizes
the essential interplay between Fas and innate immunity in the control of chemoresistant tumors.
Introduction Watanabe-Fukunaga et al., 1992). Indeed, families of patients
carrying a heterozygous mutation in the Fas gene have an in-
creased incidence of Hodgkin’s lymphoma (Fisher et al., 1995).Tumor development is driven by genetic and epigenetic events
leading to the alteration of oncogenes and tumor suppressor Fas regulation has been further shown to be key in modulating
immune homeostasis. Fas has been found to play an importantgenes. The majority of research in cancer biology has focused
on genetic mutations that contribute to human malignancy. role in the elimination of malignant cells by cytotoxic T cells and
NK cells (Ashkenazi and Dixit, 1998). Recent work on innateHowever, epigenetic phenomena such as gene silencing (re-
sulting from histone deacetylation and methylation) have also immunity suggests that NK cell function is critical in determining
the initial tumor growth (Soloski, 2001). In SCID mice, NK cellsbeen shown to contribute to tumorigenesis (Fruhwald et al.,
2001; Malik et al., 2000; Wong et al., 2000). Histone deacety- have been shown to provide antitumor immunity and their deple-
tion has been linked to metastatic spread (Zheng et al., 1996).lases (HDACs) together with histone acetyltransferases (HATs)
regulate the acetylation state of nucleosomal histones, thereby We have previously shown that over time in culture, p53
wild-type cells repress Fas expression through an acetylation-altering chromatin structure. Transcriptional silencing has been
found to increase as the level of acetylated histones increases related mechanism that is reversed by the HDAC inhibitor Tri-
chostatin A (TSA) (Maecker et al., 2000). Such epigenetic silenc-(Matzke et al., 2001; Struhl, 1998). During malignant progres-
sion, transcriptional repression could promote tumorigenesis ing of Fas in vitro could parallel similar events that occur in vivo
during malignant progression of p53 wild-type tumors acquiringby silencing cellular apoptotic effector cascades. In support of
this hypothesis, HDAC inhibitors have recently been shown to diminished apoptotic programs. We hypothesized that, if Fas
repression contributes to the apoptotic resistance of these late-induce differentiation and/or apoptosis of a variety of trans-
formed cell lines (Coffey et al., 2000; Marks et al., 2000). passage cells, restoration of Fas should restore their apoptotic
sensitivity. Further, if Fas repression contributes to the growthA key apoptotic effector, Fas (also known as APO-1 or
CD95), is a member of the TNF receptor superfamily (Nagata, of these tumors in vivo, restoration of Fas to these cells should
inhibit their growth in vivo. To determine if epigenetic silencing1997) and a downstream transcriptional target of p53 (Munsch
et al., 2000). Loss of Fas function results in hyperplasia, such of Fas affected tumor growth in vivo, we examined whether
genetic or epigenetic reversal of Fas repression impaired tumoras lymphoproliferation, which may predispose individuals to
malignancy (Adachi et al., 1993, 1995, 1996; Nagata, 1994; growth. Since previous studies linked Fas signaling to the antitu-
S I G N I F I C A N C E
The key to developing active cancer immunotherapy is to determine why the immune system initially fails to detect transformed
cells and subsequently becomes tolerant to tumor growth and metastasis. Recent work implicates a role of the host’s innate immunity
in the initial detection of transformed cells. Our observation of epigenetic silencing of Fas suggests a novel mechanism by which
p53 wild-type tumors reduce their apoptotic sensitivity and escape immune clearance. Restoration of Fas expression with histone
deacetylase inhibitors inhibits tumor growth and restores chemosensitivity in vivo in an NK cell-dependent manner. This study indicates
that the innate immune system is important not only in growth control, but also in the treatment of chemoresistant solid tumors.
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with Trichostatin A (TSA), an HDAC inhibitor. To confirm that
TSA was in fact modulating the acetylation of core histones,
we measured the levels of acetylated histone H2B and H3 from
nuclear extracts of early- and late-passage p53 wild-type MEFs
exposed to either vehicle or TSA (Figure 1B). While late-passage
p53 wild-type cells treated with vehicle exhibit very low levels
of acetylated histones, cells treated with TSA have levels of
acetylated histones equivalent with those of early-passage cells.
Hence, the transcriptional silencing of Fas observed in late-
passage p53 wild-type cells coincided with the TSA-reversible
deacetylation of core histones.
To test the contribution of Fas inactivation to apoptotic resis-
tance in the late-passage p53 wild-type cells, we altered Fas
levels either genetically (with the use of Fas-related retroviral
vectors) or pharmacologically (with TSA treatment) in the geneti-
cally defined MEF cells (Figure 2A). MEF cells were infected
with retroviral constructs expressing either a wild-type mouse
Fas construct or a dominant-interfering Fas vector (DN-Fas). As
negative controls, cells were infected with either empty vector or
another member of the Fas superfamily, p75, the low-affinity
nerve growth factor receptor. Since only the late-passage cells
demonstrated an increase in Fas expression following TSA treat-
ment (Maecker et al., 2000), these cells were the only ones to
receive this treatment in subsequent experiments.
Following either retroviral infection or TSA treatment, surface
levels of Fas were analyzed by flow cytometry (Figure 2A). With
the exception of the early-passage p53 wild-type cells, retroviral
transfection of Fas (as well as TSA treatment of the late-passage
Figure 1. Epigenetic downregulation of Fas in late-passage cells
p53 wild-type cells) resulted in an elevation of surface Fas levels.
A: Surface Fas (solid lines) and FasL (dashed lines) expression of early-pas- According to our earlier findings that the early-passage p53
sage p53 wild-type and null MEFs as well as late-passage p53 wild-type
wild-type cells possess both elevated Fas and FasL levelsMEFs. B: Nuclear histone H2B and H3 acetylation of p53 wild-type early- and
(Maecker et al., 2000), it is likely that our inability to furtherlate-passage MEFs treated for 18 hr in the presence and absence of TSA.
Late-passage MEFs demonstrate deacetylated histones characteristic of increase Fas levels in these cells is due to apoptotic induction.
transcriptional repression, which is reversed upon TSA treatment. Early-pas- This hypothesis is supported by the finding that early-passage
sage MEF histones, unlike the late-passage cells, are not deacetylated. p53 wild-type MEFs transfected with the Fas construct demon-
Actin levels are shown to illustrate equal protein loading.
strated increased basal apoptosis over the empty vector-trans-
fected MEFs (Figure 3A). Also, all cells transfected with the Fas
construct never exceeded the basal surface Fas levels found
in the early-passage p53 wild-type cells (Figure 2A).mor activity of the innate immune system (Screpanti et al., 2001),
Since the MEF cells express FasL, we tested whether thewe investigated the role of NK cells in Fas-mediated control of
above experimental manipulations altered surface FasL levels.tumor growth. In experiments with transplanted tumors derived
Increasing a cell’s surface level of Fas, either genetically orfrom cells with epigenetically silenced Fas, we investigated
pharmacologically, resulted in a parallel elevation of FasL (Figurewhether restoration of Fas expression with HDAC inhibitors re-
2B). Likewise, decreasing a cell’s surface level of Fas (with
stored chemosensitivity and inhibited tumor growth. Taken to-
DN-Fas) resulted in a parallel downmodulation of FasL. This
gether, our data illustrate a novel approach to restore chemo- effect was likely an indirect one since neither p53- nor Fas-
sensitivity of solid tumors and reengage host immune responsive elements have been reported in the FasL promoter.
surveillance. However, since MEF cells express both Fas and FasL, modula-
tion of Fas in effect dictates the activity of the Fas pathway in
Results these cells. It is possible, therefore, that a downstream target
of the Fas pathway regulates FasL levels. One possible candi-
Modulation of Fas expression date is the transcription factor NF-B. NF-B has been shown
To explore the contribution of Fas to tumor growth, we utilized to be activated downstream of Fas and is also capable of regu-
genetically defined transformed MEF cells that were wild-type lating FasL transcription (Manos and Jones, 2001).
or null in their p53 status. While early-passage p53 wild-type Transfection of DN-Fas resulted in a decrease in surface
MEFs express high basal levels of Fas and FasL, p53-deficient Fas, regardless of the cell type transfected. This decrease in
cells express low levels of Fas and FasL. Over time in culture, surface Fas was the result of inhibited trafficking of Fas to the
however, p53 wild-type cells repress Fas and FasL surface cell surface (Figure 2C). Although all cell types transfected with
expression as a means of evading fratricide-induced cell death, DN-Fas exhibited decreased Fas surface expression, their total
becoming increasingly apoptotically resistant (Figure 1A). We cellular Fas (as measured by intracellular staining) actually in-
determined previously (Maecker et al., 2000) that such Fas re- creased when compared to cells transfected with empty vector
alone.pression was due to epigenetic changes that could be reversed
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Figure 3. Fas restoration confers apoptotic sensitivity and determines tumor
growth in vivoFigure 2. Genetic and epigenetic modification of Fas
A: Percent apoptosis in MEF cells following 6 Gy ionizing irradiation. MEF cellsA: Surface Fas levels of cells retrovirally transfected with empty vector, p75,
either transfected with Fas or treated with TSA demonstrated an increase inDN-Fas, or Fas or treated with TSA. Transfection of Fas increased surface Fas
their apoptotic sensitivity in response to irradiation. Cells transfected withlevels, whereas transfection of DN-Fas resulted in a decrease in surface Fas.
DN-Fas were protected against radiation-induced apoptosis. TransfectionEmpty vector and p75 failed to affect surface Fas expression. TSA treatment
of empty vector or p75 didn’t alter the ability of MEF cells to undergoof p53/, p20 cells resulted in an increase in their surface Fas expression.
radiation-induced cell death. Restoration of surface Fas either geneticallyB: Surface FasL of genetically modified and epigenetically modified MEFs.
or pharmacologically restored the ability of late-passage cells to undergoTransfection of Fas and TSA increased surface FasL. Transfection of DN-Fas
radiation-mediated apoptosis. B: Time course of tumor growth of SCID micereduced surface FasL. Transfection of empty vector and p75 had no effect.
injected with MEF cells transfected with the designated constructs or treatedC: Intracellular Fas staining of cells transfected with empty vector or DN-Fas.
with TSA. Elevating tumor Fas greatly inhibited growth in vivo. Likewise, inhib-Surface Fas expression is shown by a solid black line and intracellular Fas
iting tumor Fas (DN-Fas) accelerated tumor growth. On day 27 a mousestaining by the gray fill. Transfection of DN-Fas decreased the surface Fas
injected with p53/, p20 DN-Fas tumor cells died; on day 28 a mouseexpression even though intracellular levels of Fas increased. DN-Fas thus
injected with p53/, p20 empty vector died. The causes of these deathsinhibited Fas protein trafficking to the cell surface.
were not determined. C: Final tumor weight of mice on day 28 postinjection.
Fas restoration confers apoptotic sensitivity induced apoptosis. Further, decreasing surface Fas (with
and determines tumor growth in vivo DN-Fas) protected cells from radiation-induced cell death. This
Having confirmed that we were able to modify surface levels of effect was specific to Fas in that p75 failed to affect apoptotic
Fas, we next investigated apoptotic sensitivity of these cells. sensitivity regardless of cell type. Further, the alteration in apo-
MEFs were exposed to 6 Gy ionizing radiation, and apoptosis ptotic sensitivity was greatest in cells possessing wild-type p53,
was measured at 0, 6, 12, and 24 hr following treatment (Figure arguing for the importance of p53 in maximal activation of the
Fas death machinery.3A). Increasing surface Fas enhanced both basal and radiation-
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Having shown that we were able to alter Fas levels as well
as apoptotic sensitivity in vitro, we tested whether this would
correlate with tumor growth in vivo. One-half million p53 wild-
type early-passage, late-passage, or null MEFs transfected with
empty vector, Fas, DN-Fas, or p75 or treated with TSA were
injected into C57BL/6J SCID mice, and tumor growth was moni-
tored over 1 month. Tumor growth was analyzed by determining
tumor volume over time (Figure 3B) and final tumor weight (Fig-
ure 3C). Consistently, tumor cells expressing the lowest levels
of Fas grew the largest tumors; conversely, tumor cells express-
ing the highest Fas levels grew the smallest tumors or failed
to implant altogether. Late-passage p53 wild-type cells with
repressed Fas demonstrated the fastest growth rate (Figure 3B)
as well as the largest tumor weight (Figure 3C). p53 null cells,
expressing low levels of Fas, grew at a slower rate and achieved
a smaller final tumor weight (approximately half that of the late-
passage cells). Early-passage p53 wild-type cells, with high
levels of Fas, either failed to take altogether or achieved tumor
weights 10-fold smaller than the late-passage cells. Further,
late-passage p53 wild-type MEFs with genetic or epigenetic
Fas restoration were inhibited in their growth in vivo or, in the
case of the TSA-treated cells, failed to implant. Of note, inhibi-
tion of Fas signaling (by transfection of DN-Fas) completely
ablated the growth advantage of p53 null cells over early-pas-
sage p53 wild-type cells. As with our earlier in vitro data, trans-
fection of p75 failed to affect the course of tumor growth of any
of the MEF cells, demonstrating that differences in tumor growth
were Fas dependent.
NK cells provide Fas-dependent tumor immunity
To understand the immune basis of Fas-mediated tumor growth
Figure 4. NK cells regulate Fas-mediated tumor clearancein vivo, the above experiments were repeated in NK-deficient
A: The median of five NK-deficient SCID beige mice is shown for eachSCID beige mice. One-half million p53 wild-type early-passage,
experimental group. B: Time course of tumor growth in SCID beige mice.late-passage, or null MEFs were injected into SCID beige mice,
Tumor Fas levels no longer determined tumor growth. On day 22, one mouse
and tumor growth was monitored over 1 month (Figures 4A and injected with p53/, p5 tumor cells died; on day 28 one mouse injected
with p53/, p5 tumor cells died. The causes of these deaths were not4B). In the absence of NK cells, Fas levels failed to determine
determined. C: In vitro basal proliferation of MEF cells. Suppression of surfacetumor growth, as evidenced by the lack of difference between
Fas levels with DN-Fas abolished the difference in growth rate between
the growth of the early- and late-passage p53 wild-type MEFs p53/, p5 and p53/, p20 cells.
(Figures 4A and 4B).
To understand why the p53 null MEF tumors grew slower
than the p53 wild-type tumors, in vitro proliferation assays were
Epigenetic modification of Fas restoresconducted (Figure 4C). It has been suggested that in immuno-
chemotherapeutic responsivenesscompetent hosts, tumor growth is a balance between prolifera-
of established tumors in vivotive and apoptotic indices (Evan and Vousden, 2001). In SCID
We next investigated if Fas modulation in established, apo-beige mice that lack NK apoptotic effectors, we hypothesized
ptotically resistant tumors would sensitize them to chemothera-that proliferation rates would determine tumor growth. Indeed,
peutic attack and immune clearance. To address this issue,the early-passage p53 null MEFs were found to proliferate more
we first measured apoptosis in the late-passage p53 wild-type
slowly in vitro than the late-passage p53 wild-type MEFs, al-
MEFs (with repressed Fas) induced by various chemotherapeu-
though these p53 null MEFs proliferated faster than the early- tic agents in the presence and absence of TSA. In the absence
passage p53 wild-type cells (Figure 4C). However, when Fas of TSA, the late-passage cells were resistant to chemotherapy-
was inactivated in the early-passage p53 wild-type MEFs (with induced killing, whereas in the presence of TSA they were effec-
DN-Fas to prevent fratricide-induced death resulting from cell- tively eliminated (Figure 5A). This sensitization was directly at-
cell contact in vitro), their proliferative potential was identical to tributable to reversal of Fas repression (and not a secondary
the late-passage cells. Thus, in SCID beige mice, Fas failed to effect of TSA), since late-passage cells transfected with the
influence proliferative potentials. These data suggest that in the DN-Fas construct were protected against chemotherapeutic at-
absence of innate immunity, proliferative indices rather than tack even in the presence of TSA.
Having confirmed in vitro that we were able to sensitize late-apoptotic regulators dictate tumor growth rates.
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Figure 5. The in vitro and in vivo roles of Fas in tumor chemosensitivity
A: In vitro apoptosis of late-passage MEFs in response to chemotherapy Figure 6. Epigenetic restoration of Fas in established tumors and chemosen-
was analyzed in the presence and absence of TSA. Late-passage MEFs sitivity
resistant to chemotherapeutic drugs are sensitized in the presence of TSA. A: In vivo tumor Fas levels. Tumor cells harvested from a parallel group of
This effect is directly attributable to the reexpression of Fas in that late- treated mice 12 hr following the first treatment (day 11) and 24 hr following
passage cells transfected with the DN-Fas construct are protected from the third treatment (day 17). Flow cytometry data displayed from the me-
killing even in the presence of TSA. B: The median mouse of five of each dian tumor (of five treated per group). Dotted line, saline/DMSO treated;
experimental group receiving the designated treatment on day 10, 13, and dashed line, etoposide treated; solid line, TSA-treated; bold solid line, etopo-
16 post-tumor injection. C: Time course of tumor growth. Arrows represent side plus TSA treated. Only one mouse of five receiving the combination of
when treatment was administered. On day 28, one mouse receiving TSA etoposide plus TSA still had tumor cells to recover on day 17 for analysis of
treatment died, of undetermined cause. Fas/MHC I expression. B: Histogram summary of in vivo Fas levels of tumors
isolated from above treated mice. Tumor cells isolated from mice receiving
the combination of etoposide plus TSA demonstrate the highest levels of Fas.
C: Growth of DN-Fas-transfected tumors over time in SCID mice receiving the
passage MEFs to chemotherapy-induced killing, the question above treatments on day 10, 13, and 16 post-tumor injection as indicated
by arrows. TSA enhancement of etoposide chemosensitivity observed inarose whether established, late-passage tumors in vivo would
Figures 5B and 5C was directly attributable to Fas modification as demon-exhibit such sensitization. To test this hypothesis, one-half mil-
strated by the finding that tumor cells transfected with DN-Fas failed tolion late-passage p53 wild-type MEFs were injected into the
regress or retard their growth.
hind flank of C57BL/6J SCID mice. Ten days postinjection, the
mice were randomly assigned to one of four treatment groups:
saline plus DMSO, etoposide, TSA, or etoposide plus TSA. Tu-
mor-bearing mice were treated on day 10, 13, and 16. Tumors plus DMSO grew at similar rates, achieving near identical vol-
umes as tumors receiving etoposide chemotherapy. While TSA-were measured over 1 month (Figures 5B and 5C). Additionally,
in order to ascertain if the effectiveness of chemotherapeutic treated mice grew smaller tumors, on average, they failed to
differ statistically from mice receiving either saline plus DMSO ortreatments correlated with in vivo modification of tumor Fas
expression, a second group of mice was treated in parallel so etoposide alone. However, mice receiving both TSA and etoposide
dramatically responded to treatment by either arresting furtherthat tumors could be analyzed at designated times following
the treatments (Figures 6A and 6B). growth or regressing altogether (Figures 5B and 5C).
Fas was indeed found to be repressed during the courseTumors derived from late-passage MEFs were chemother-
apy resistant (Figures 5B and 5C). Tumors treated with saline of tumor progression, as evidenced by the significantly lower
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levels of tumor Fas exhibited on day 17 when compared to
levels on day 11 post-tumor implantation (Figures 6A and 6B).
These in vivo data replicate what we previously had found in
vitro (Maecker et al., 2000). Further, tumor Fas modification
indeed correlated with therapeutic response (Figures 6A and
6B). Tumors harvested from mice receiving the combination
TSA and chemotherapy treatment exhibit greatly elevated Fas
levels over tumors isolated from mice receiving the other treat-
ments. These results demonstrate that epigenetic factors are not
only capable of regulating tumor growth, but they also influence
therapeutic response.
To test whether Fas modification was in fact required for
enhancement of chemotherapeutic responses by TSA, the che-
motherapy experiments were repeated in C57BL/6J SCID mice
with tumor cells retrovirally transfected with DN-Fas. Reversal
of tumor Fas repression was found to be critical to therapeutic
response in that late-passage tumor cells transfected with
DN-Fas failed to arrest or regress when treated with the combi-
nation of TSA and etoposide (Figure 6C). These data demon-
strate that Fas restoration is required for the restoration of tumor
chemotherapeutic responsiveness.
Modification of MHC I levels fail to mediate restoration
of chemotherapeutic responsiveness
One explanation for the enhanced therapeutic response ob-
served in mice receiving the combination TSA/chemotherapy
treatment is modification of tumor MHC I levels. To address
this issue, we analyzed tumor MHC I levels from the treated
mice in conjunction with Fas. However, unlike Fas, tumor MHC
I levels failed to differ statistically, among any of the groups at
any of the tumor harvest times, with the exception of 24 hr
following the third treatment (Figure 7A). MHC I levels of tumors
receiving the combination TSA and chemotherapy treatment
were greater than levels of mice receiving the other treatments.
One explanation is that selection occurred during the course of
treatment, with cells expressing the lowest levels of MHC I
Figure 7. MHC I levels do not change in response to chemotherapy, TSA,having been eliminated earlier by NK cells during the first or
or the combination chemotherapy plus TSAsecond round of treatment. In support of this, most of the tumor
A: Histogram summary of in vivo MHC I (H-2Kb) tumor levels from treatedcells isolated on day 17 from mice receiving the combination
mice. B: Histogram summary of in vitro flow cytometry data of surface MHCtreatment were dead (as evidenced by staining with a vital dye
I (H-2Kb) levels of primary and transformed p53 wild-type MEFs 24 hr following
7-ADD; data not shown) and excluded from Fas/MHC I analysis. treatment with saline plus DMSO, etoposide, TSA, and etoposide plus TSA.
In order to delineate the effects of TSA and chemotherapy C: Histogram summary of in vitro flow cytometry data of surface MHC I
(H-2Db) levels of primary and transformed MEFs. Chemotherapeutic treat-upon MHC I modulation apart from confounding effects resulting
ment and/or TSA exposure fails to affect surface levels of MHC I proteins.from effector-mediated tumor elimination that occur in vivo,
analysis of the mouse surface MHC I proteins were conducted
in vitro (Figures 7B and 7C). Primary p53 wild-type MEFs as
well as E1A/Ras-transformed MEFs were treated for 24 hr with
NK cells mediate chemotherapeutic responsivenesssaline plus DMSO, etoposide, TSA, and the combination of
To determine whether NK effector function was essential for theetoposide and TSA. Surface MHC I levels of the H-2Kb (Figure
restoration of chemotherapeutic response, NK-deficient SCID7B) and H-2Db (Figure 7C) proteins were analyzed by FACS.
beige mice bearing late-passage tumors were treated with salineConsistent with published work (Ishido et al., 2000; Johnsen et
plus DMSO, etoposide, TSA, or the combination of TSA andal., 1999; Maudsley and Pound, 1991), transformation resulted
etoposide. None of these groups differed in tumor size (Figurein a surface downmodulation of both MHC I proteins. Also in
8A). These data suggest that although tumors from mice receiv-line with reported data (Ishido et al., 2000; Johnsen et al., 1999),
ing the combination of TSA plus etoposide treatment elevatedsurface MHC I levels decreased with increasing passage in
their surface levels of Fas in vivo (Figures 6A and 6B), in thetransformed cells promoting a role of MHC I downmodulation
absence of FasL-expressing NK effectors, their apoptotic pro-as a means of enhancing tumor immune escape. However,
grams fail to be engaged. Thus, NK cell function is required foralthough transformation and increasing passage both modu-
the Fas-mediated restoration of chemotherapeutic respon-lated surface MHC I levels, chemotherapy and/or TSA treatment
siveness of these tumors.did not. These findings support the hypothesis that modulation
To address the possible issues of strain background uponof tumor Fas levels, and not surface MHC I, is responsible for
the enhancement of chemotherapeutic responsiveness. the chemotherapeutic effect, NK tumoricidal activity was mea-
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tumor cells transfected with DN-Fas were protected from NK-
mediated elimination. Thus, in tumor cells with repressed Fas,
epigenetic modulation of Fas restored chemosensitivity by en-
gaging NK-mediated clearance.
Lastly, to confirm that NK cells were indeed infiltrating into
the tumors of treated mice to exert potential tumoricidal effects,
tumors isolated from mice receiving the various chemothera-
peutic regimens (Figures 5B, 5C, 6A, and 6B) were harvested
and stained for their presence of NK cells (Figure 8C). Surpris-
ingly, elevated NK infiltration was only found to be present in
tumors isolated from mice receiving the combination of chemo-
therapy plus TSA. This finding, coupled with the in vitro finding
that NK tumoricidal activity is only enhanced against cells re-
ceiving the combination therapy, raises the possibility that the
combination of TSA and chemotherapeutic treatment provides
additional costimulatory signals to the NK cells that are not
provided by the other treatments alone. Our data further empha-
size that the synergy between tumor Fas and infiltrating NK
cells is able to enhance chemosensitivity and modulate tumor
growth.
Discussion
This work, although based on a highly idealized p53 model
system, provides a mechanism for the chemotherapeutic resis-
tance observed in p53 wild-type tumors and suggests modula-
tion of Fas expression as a therapeutic target. Our data suggest
that HDAC inhibitors, such as TSA, potentially increase the effi-
cacy of chemotherapeutic agents by restoring apoptotic effector
arms silenced during tumor progression.
During malignant progression, epigenetic changes in the
expression of p53’s downstream target genes may indeed occur
before p53 inactivation. Specifically, Fas repression may be an
Figure 8. NK cells are required for Fas-mediated sensitization of established early event in some tumors, resulting in the malignant growth
tumors to chemotherapy and immune clearance of tumor cells with wild-type p53. Interestingly, oncogenic
A: Time course of tumor growth of late-passage MEFs in SCID beige mice H-Ras has recently been found to be capable of suppressing
(NK-deficient). Treatment was administered as on day 10, 13, and 16 post-
Fas mRNA through hypermethylation of the Fas gene in vitrotumor injection as indicated by arrows. NK cell function was found to be
(Peli et al., 1999). Oncogenic activation could thus potentiallycritical for TSA enhancement of etoposide chemosensitivity in that SCID
beige mice receiving the combination of TSA and etoposide failed to re- predispose a cell to malignant transformation by silencing Fas
gress or slow tumor growth. B: NK tumoricidal activity. TSA restoration of and hence disabling an effector arm of p53’s apoptotic program
tumor Fas expression in etoposide-treated tumor cells was found to enhance (Johnstone et al., 2002).
NK-mediated cell death that was not observed in tumor cells treated with
Elegant studies have suggested that the Fas pathway canetoposide alone or in tumor cells transfected with DN-Fas receiving both
signal either proliferation or apoptosis, depending upon the de-TSA and etoposide. The solid lines represent tumor cell lysis of late-passage
MEFs transfected with empty vector, whereas the dashed lines represent velopmental and activation state of lymphocytes (Siegel et al.,
tumor cell lysis of late-passage MEFs transfected with DN-Fas. C: Percentage 2000). Freshly isolated human T cells in vitro have been reported
of tumor infiltrating NK cells in vivo (from Figures 6A and 6B, treated mice). to proliferate in response to activating Fas antibodies and anti-
Tumors isolated from mice receiving the designated treatments were co-
CD3 stimulation (Alderson et al., 1993). These findings raisestained for CD45 (common leukocyte antigen) and the Pan-NK cell anti-
the possibility that tumor downregulation of Fas may not onlybody (DX5) to calculate the percentage of tumor-infiltrating NK cells. Only
tumors isolated from mice receiving the combination of etoposide plus TSA suppress the tumor’s apoptotic sensitivity, but may also hinder
treatment exhibited increased NK cell infiltration (only one mouse of five the expansion of immune effectors. The Fas apoptotic effector-
receiving the combination of etoposide plus TSA still had tumor cells on day dependent control of tumor growth is supported by our previous
17 for analysis).
studies in which we showed that FasL was required for Fas-
mediated killing (Maecker et al., 2000).
Although the Fas-deficient lpr and FasL-deficient gld sys-
tems have been used to evaluate the role of Fas/FasL in apopto-sured directly (Figure 8B). NK cells harvested from C57BL/6J
sis, the lpr defect is leaky both at the mRNA and protein levelsSCID mice were utilized as effector cells in chromium release
(Adachi et al., 1996; Booker et al., 1998). Notably, lpr cellsassays. Late-passage MEF cells (retrovirally transfected with
express significant amounts of Fas in response to genotoxiceither empty vector or DN-Fas) treated with saline plus DMSO,
stress such as -irradiation (Booker et al., 1998). Therefore, weetoposide, TSA, or etoposide plus TSA were used as targets.
reasoned that genetic and/or epigenetic manipulation of Fas inNK-mediated killing was substantially enhanced in tumor cells
the isogenic MEF cells would provide a much “cleaner” systemreceiving the combination of etoposide plus TSA. This enhanced
death was attributable to reversal of tumor Fas repression as to address the role of tumor Fas in chemosensitivity and tumor
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control by the innate immune system. An alternative experiment vide a viable approach for efficient tumor control. In the future,
would be the implantation of the MEF tumors in gld mice lacking it will be important to determine if the chemosensitivity of human
FasL. However, this approach would be difficult to interpret spontaneous tumors is also influenced by Fas and NK cells.
due to their different genetic backgrounds. To overcome these
Experimental proceduresproblems, we chose to manipulate tumor Fas both genetically
with wild-type or dominant-negative Fas and epigenetically with
Cell lines
TSA, and to address the role of NK cell function using the NK- Cell lines were generously provided as follows: mouse embryonic fibroblasts
positive SCID and NK-deficient SCID beige mice. (MEFs) on a C57BL/6J background transformed with E1A/Ha-Ras, either
The role of Fas/FasL in DNA damage-induced apoptosis wild-type or null for p53 (Scott Lowe, MIT, Cambridge, MA); amphotropic
Phoenix retrovirus-producing cells (Gary Nolan, Stanford University, CA);has been established in a variety of cell types including many
amphotropic Phoenix cells lines stably transfected with the mouse ecotropictumor cells (Bennett et al., 1998; Eichhorst et al., 2001; Friesen
receptor (J. Norton, University of Pennsylvania, PA); and ecotropic Phoenixet al., 1996; Houghton et al., 1997; Kolbus et al., 2000). Cells
retrovirus-producing cells (Gary Nolan, Stanford University, CA). The E1A/derived from lpr mice such as MEFs in vitro and thymocytes in
ras-transformed MEF cells were originated from clonal populations. MEF
vivo exhibit resistance to apoptosis induced by DNA damage cells at passage 5 or passage 20 were generated by consecutive in vitro
(Bennett et al., 1998; Eichhorst et al., 2001). However, Newton culture without any selection (Maecker et al., 2000). All cells were grown in
and Strasser (2000) showed that normal lymphocytes from lpr DMEM supplemented with 10% fetal bovine serum and antibiotics (GIBCO-
BRL, Grand Island, NY).mice were sensitive in vitro to -irradiation and DNA-damaging
agents in a p53-dependent manner. Such reported discrepan-
Plasmid constructscies are likely due to differences in cell types and/or in cellular
The mouse Fas and DN-Fas constructs were a gift of Robert Wiltrout, NCI.microenvironments found in vitro versus in vivo. For example,
The p75 construct was a gift of Moses Chao, New York University School
the p53-dependent bax expression may potentially account for of Medicine. These constructs were subcloned into the EcoRI site of the
the apoptotic sensitivity of the lpr lymphocytes observed by pBabe puro retroviral vector backbone (Morgenstern and Land, 1990a,
Newton and Strasser (2000). 1990b) and were confirmed by DNA sequence analysis.
HDAC inhibitors, such as TSA, potentially have a multitude
Retroviral infection of MEF cellsof cellular effects. However, studies have found that only a small
Retroviral production and infection were modified from existing protocolsportion (about 2%) of genes alter their expression patterns in
(Baker et al., 1992; Pear et al., 1993). Briefly, amphotropic Phoenix cellsresponse to HDAC inhibitors (Marks et al., 2000). In this study,
(Pear et al., 1993) were transfected with the mouse ecotropic viral receptor
we also analyzed class I MHC (H-2Db and H-2Kb) expression (Baker et al., 1992) and stable clones were generated. These amphotropic
after TSA treatment both in vivo and in vitro. Our results indicate Phoenix cells expressing the mouse ecotropic receptor were then used in
that TSA has little effect on the expression of MHC I molecules, coculture with ecotropic viral-producing cells to generate high-titer retrovirus
according to the published protocol (Pear et al., 1993). Viral supernatantdespite the fact that MHC I molecules are further reduced in
was collected from these cocultures, supplemented with 8 g/ml polybrene,late-passage cells. In addition, genetic manipulation of Fas ex-
and added undiluted to MEF cells plated into 6-well plates. These platespression with wild-type and dominant-negative Fas lends further
were then centrifuged at room temperature at 300  g for 45 min. Cellssupport for the role of the Fas apoptotic effector arm in tumor
were placed into a 32C incubator for 11 hr to allow viral infection. This
chemosensitivity and tumor control in vivo. procedure was repeated every 12 hr with fresh virus for two additional times.
It has been reported that many tumor cells are sensitive in Following the third infection, remaining virus was removed and replaced
vitro to killing by NK cells (Bradley et al., 1998; Long et al., 1997; with fresh medium. Cells were then allowed to recover for 12 hr in a 37C
Ravetch and Lanier, 2000; Tanaka et al., 1995). Upon activation, incubator prior to experimental analysis. The pool of retrovirally transfected
cells was used in subsequent experiments.NK cells elevate their surface expression of FasL and initiate
apoptosis in their target via the Fas pathway (Montel et al.,
Cell treatments1995). Further, NK cell depletion has been found to promote
MEF cells transfected with various retroviral constructs (see above) weremetastatic spread (Zheng et al., 1996). Most recently, Fas has
irradiated with 600 cGy at a dose rate of 281 cGy/min from a 137Cs source
been shown to play a central role in the rejection of tumors by in the presence and absence of 25 nM TSA. Apoptosis (see below) was
NK cells (Screpanti et al., 2001). We report here that epigenetic measured 6, 12, and 24 hr following irradiation. Chemotherapeutically treated
regulation of Fas determines tumor growth as well as chemo- MEFs in vitro received 2 g/ml cisplatin, etoposide, or doxorubicin dissolved
therapeutic resistance of established tumors. Both of these pro- in saline plus 10% DMSO, and apoptosis was measured at 18 and 36 hr
following drug administration. In vitro proliferation assays were conductedcesses are dependent upon NK cells.
by plating 10,000 MEF cells/100 l/well in triplicate on a 96-well plate. CellsThe differences between in vivo and in vitro phenomena
were allowed 1 hr to adhere prior to loading with one Ci/well 3H-thymidinecan be attributed, at least in part, to differences in the tumor
in 100 l medium. Following 18 hr, cells were harvested and read on amicroenvironment. Tumor cells are in direct cell-cell contact
-scintillation counter.
with each other when cultured in vitro, and are limited by contact
inhibition. Thus, expression of Fas (with the concomitant expres- Flow cytometry analysis
sion of FasL) is sufficient in vitro for etoposide-induced apopto- Surface levels of Fas and FasL were measured by incubating 1  106 cells
on ice for 30 min with 1 g/ml of biotinylated anti-Fas Ab, Jo2 (BD Phar-sis. However, tumor cells in vivo are not necessarily regulated
mingen, San Diego, CA), anti-FasL Ab, Kay-10 (BD Pharmingen), or anin the same manner. Rather, a synergistic role of tumor Fas and
irrelevant isotype control. Cells were subsequently washed and incubatedhost NK cells is needed to achieve chemosensitivity in vivo.
for an additional 30 min with Streptavidin-PE (BD Immunocytometry Sys-This observation underscores the importance of the tumor mi-
tems, San Jose, CA). Following a final wash, cells were analyzed on acroenvironment.
FACSCalibur flow cytometer (BD Immunocytometry Systems). All experi-
In summary, our data illustrate the importance of Fas and ments were conducted a minimum of three times.
innate immunity in modulating tumor growth kinetics and che- Intracellular Fas staining of MEF cell lines retrovirally transfected with
mosensitivity in vivo. Our study implies that upregulation of either empty vector or the DN-Fas construct was conducted according to
the previously published method of Bennett et al. (1998).tumor Fas coupled with engagement of host immunity can pro-
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Staining for MHC alleles was done using antibodies to H-2Kb and H-2Db vested from the treated mice for analysis of surface Fas and MHC I (H-2Kb)
levels by FACS analysis. Infiltrating immune cells were identified by staining(0.5 g each) along with 7-AAD to exclude dead cells (all reagents from BD
with CD45 FITC, and NK cells were further classified by staining with thePharmingen). Antibody staining was done for 30 min on ice, followed by
Pan-NK antibody, DX5 PE (BD Pharmingen).washing and addition of 7-AAD as recommended by the supplier.
To confirm the importance of Fas to the enhancement of chemosensitiv-
ity observed with TSA, late-passage MEF cells retrovirally transfected withApoptosis assays
DN-Fas were injected into the hind flank of C57BL/6J SCID mice. Ten daysApoptosis was determined by staining cells with the APO-DIRECT Kit (BD
following tumor injection, the mice were randomly assigned to one of fourPharmingen) followed by analysis on a FACSCalibur flow cytometer (BD
treatment groups (each group containing five mice): saline plus DMSO,Immunocytometry Systems). The APO-DIRECT assay detects DNA strand
etoposide, TSA, and etoposide plus TSA, as described above. Tumor growthbreaks. All experiments were repeated three times.
was monitored over 1 month.
To test the importance of NK cell activity in the enhancement of chemo-Analysis of Fas and FasL expression in late-passage cells
sensitivity observed with TSA, late-passage p53 wild-type MEFs were in-Genomic sequencing of Fas and FasL was conducted to confirm that no
jected into the hind flank of CB.17 SCID beige mice (lacking NK cells). Again,mutations occurred in these genes in the late-passage wild-type MEFs.
10 days following tumor injection, the mice were randomly assigned to oneProtein surface expression and mRNA expression were analyzed by flow
of the four treatment groups (each group containing five mice), and treatmentcytometry and RNase protection assay (BD Pharmingen). DNA acetylation
was conducted as described above. Tumor growth was monitored over 1status was analyzed by comparing mRNA levels of Fas and FasL treated in
month.the presence and absence of TSA as well as by analysis of acetylated
Histone H3 levels of nuclear extracts of cells treated in the presence and
51Cr release assaysabsence of TSA. mRNA was isolated from late-passage cells treated with
Splenocytes were harvested from C57BL/6J SCID mice, depleted of erythro-the HDAC inhibitor TSA (Sigma Chemical Company, St. Louis, MO), adminis-
cytes by ammonium chloride lysis, and cultured (2.5  106 /ml) for 4 days
tered at 25 ng/ml for 24 hr. Acetyl-Histone H3 levels were determined from
in 1000 U/ml of human rIL-2 (PeproTech, Rocky Hill, NJ) to generate NK
Western blots of nuclear extracts of cells either untreated or treated with
effectors. Twelve hours prior to the initiation of the assay, 5000 tumor cells
TSA (50 ng/ml) for 18 hr. Five micrograms of nuclear extract were loaded
were plated per well onto flat-bottom 96-well plates and allowed to adhere
per well onto an Invitrogen 10% Tris-Bis gel with MES running buffer and overnight. The following day, tumor cells were exposed for 6 hr to one of
run according to the manufacturer’s instruction. Protein was transferred onto the four treatments: saline plus DMSO, etoposide (2 g/ml), TSA (25 nM),
nitrocellulose (Invitrogen, Carlsbad, CA) and blocked overnight at 4C in or etoposide plus TSA (all conditions done in triplicate). Following treatment,
Tris-buffered saline containing Tween-20 with 5% (w/v) nonfat dry milk. tumor cells were washed and loaded with 25 l of medium containing 1
Following the overnight incubation, the membrane was incubated with either mCi/ml Na[51Cr]O4 for 1.5 hr. After loading, cells were washed four times
anti-Acetyl-Histone H2B or anti-Acetyl-Histone H3 pAb (Cell Signaling Tech- and NK effectors were added directly to the wells. The NK effectors were
nology, Beverly, MA) at a dilution of 1:1000. The secondary antibody em- incubated with the tumor targets for 10 hr prior to harvesting. Specific lysis
ployed was an anti-rabbit IgG HRP (New England Biolabs, Beverly, MA) at was calculated according to the formula: % lysis  [(experimental release 	
a dilution of 1:5000. The membrane was reprobed with an anti-actin antibody spontaneous release) / (maximum release 	 spontaneous release)]  100.
(ICN, Carlsbad, CA) at a dilution of 1:20,000 followed by secondary incuba-
tion with anti-mouse IgG HRP (BD Pharmingen) used at a dilution of 1:20,000 Acknowledgments
to ensure equal loading. The membrane was then processed with ECL
reagent and film-scanned. We thank Sharon Clarke for excellent secretarial assistance. This work was
supported by NIH grants CA88480 and CA67166 (A.J.G.) and NIH Cancer
Mouse experiments Biology Training Grant CA09302 (Z.Y.).
The ability of Fas expression to regulate tumor growth was analyzed with
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